Published in Circulation on January 01, 1991
Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ (2015) 2.40
Differential regulation of two types of intracellular calcium release channels during end-stage heart failure. J Clin Invest (1995) 1.78
Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc (2010) 1.51
Recommendations on the management of pulmonary hypertension in clinical practice. Heart (2001) 1.28
Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. Vasc Health Risk Manag (2010) 1.16
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics (2011) 1.12
Expression of dihydropyridine receptor (Ca2+ channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure. J Clin Invest (1992) 1.06
Blockade of I(Ca) suppresses early afterdepolarizations and reduces transmural dispersion of repolarization in a whole heart model of chronic heart failure. Br J Pharmacol (2012) 0.92
Remodeling of calcium handling in human heart failure. Adv Exp Med Biol (2012) 0.91
Atrial fibrillation in heart failure: what should we do? Eur Heart J (2015) 0.86
Vascular versus myocardial effects of calcium antagonists. Drugs (1994) 0.81
Management of Hypertension among Patients with Coronary Heart Disease. Int J Hypertens (2011) 0.79
Calcium channel blockers and congestive heart failure. Circulation (1991) 0.79
Pharmacological treatment of chronic heart failure. Heart Fail Rev (2006) 0.79
The treatment of heart failure--what next? Br J Clin Pharmacol (1993) 0.78
Secondary prevention with calcium antagonists after acute myocardial infarction. Drugs (1992) 0.77
Effects of the calcium channel blockers, diltiazem and Ro 40-5967, on systemic haemodynamics and plasma noradrenaline levels in conscious dogs with pacing-induced heart failure. Br J Pharmacol (1994) 0.77
Comorbidity of atrial fibrillation and heart failure. Nat Rev Cardiol (2015) 0.76
How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: remodelling, resetting, or sudden death? Br Heart J (1994) 0.76
Relationship between calcium channel blocker class and mortality in dialysis. Pharmacoepidemiol Drug Saf (2015) 0.75
Modification of atherosclerosis by agents that do not lower cholesterol. Br Heart J (1993) 0.75
Long-acting calcium channel antagonist pranidipine prevents ventricular remodeling after myocardial infarction in rats. Heart Vessels (1999) 0.75
Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open Heart (2016) 0.75
Atrial fibrillation in heart failure: The sword of Damocles revisited. World J Cardiol (2013) 0.75
Understanding and Managing Atrial Fibrillation in Patients with Kidney Disease. J Atr Fibrillation (2015) 0.75
Effect of contraindicated drugs for heart failure on hospitalization among seniors with heart failure: A nested case-control study. Medicine (Baltimore) (2017) 0.75
Optimising heart failure pharmacotherapy: the ideal combination. Br Heart J (1994) 0.75
Gene therapies for arrhythmias in heart failure. Pflugers Arch (2014) 0.75
Use of Inotropic Agents in Treatment of Systolic Heart Failure. Int J Mol Sci (2015) 0.75
Are calcium antagonists safe in hypertension? Postgrad Med J (1996) 0.75
Medical treatment beyond ACE inhibition: false promise or lack of vision? Br Heart J (1994) 0.75
Characterization and bioactivity of novel calcium antagonists - N-methoxy-benzyl haloperidol quaternary ammonium salt. Oncotarget (2015) 0.75
The ever expanding spectrum of ischemic left ventricular dysfunction. Cardiovasc Drugs Ther (1994) 0.75
ACE inhibitors and calcium antagonists in the treatment of congestive heart failure. Cardiovasc Drugs Ther (1995) 0.75
Neurohormones in patients with ischemic left ventricular dysfunction. Cardiovasc Drugs Ther (1994) 0.75
Prevention of and medical therapy for atrial arrhythmias in heart failure. Heart Fail Rev (2002) 0.75
Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circ J (2017) 0.75
Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med (1997) 4.51
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med (2000) 4.27
Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation (1999) 4.24
Ionic mechanisms underlying human atrial action potential properties: insights from a mathematical model. Am J Physiol (1998) 3.41
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med (1995) 3.32
Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res (1993) 2.71
Mechanism of propranolol withdrawal phenomena. Circulation (1979) 2.66
Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ Res (1996) 2.50
Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res (1997) 2.38
Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med (2000) 2.27
Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation (2001) 2.27
Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current. Circ Res (1993) 2.02
Potential molecular basis of different physiological properties of the transient outward K+ current in rabbit and human atrial myocytes. Circ Res (1999) 1.94
Accuracy of polyp detection by gastroenterologists and nurse endoscopists during flexible sigmoidoscopy: a randomized trial. Gastroenterology (1999) 1.91
Effectiveness and patient satisfaction with screening flexible sigmoidoscopy performed by registered nurses. Gastrointest Endosc (1999) 1.89
Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation (2000) 1.83
Potential ionic mechanism for repolarization differences between canine right and left atrium. Circ Res (2001) 1.79
Differing sympathetic and vagal effects on atrial fibrillation in dogs: role of refractoriness heterogeneity. Am J Physiol (1997) 1.72
Rapid and slow components of delayed rectifier current in human atrial myocytes. Cardiovasc Res (1994) 1.67
Effects of the chromanol 293B, a selective blocker of the slow, component of the delayed rectifier K+ current, on repolarization in human and guinea pig ventricular myocytes. Cardiovasc Res (1998) 1.66
Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc Res (1999) 1.61
Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc Res (2001) 1.60
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation (1994) 1.57
Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. Circ Res (1997) 1.57
Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res (1999) 1.56
Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation (1997) 1.51
Differential distribution of inward rectifier potassium channel transcripts in human atrium versus ventricle. Circulation (1998) 1.50
Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial. Eur Heart J (2002) 1.50
Mathematical analysis of canine atrial action potentials: rate, regional factors, and electrical remodeling. Am J Physiol Heart Circ Physiol (2000) 1.50
Bedside blood glucose determinations in critical care medicine: a comparative analysis of two techniques. Crit Care Med (1982) 1.46
Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. Diabetes Care (1999) 1.43
Transmembrane ICa contributes to rate-dependent changes of action potentials in human ventricular myocytes. Am J Physiol (1999) 1.42
Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. CCAIT Study Group. Circulation (1996) 1.37
Delayed rectifier outward current and repolarization in human atrial myocytes. Circ Res (1993) 1.35
Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther (1995) 1.34
Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial electrical remodeling. Circulation (1998) 1.33
Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther (2001) 1.33
Ionic mechanisms of regional action potential heterogeneity in the canine right atrium. Circ Res (1998) 1.24
Transient outward and delayed rectifier currents in canine atrium: properties and role of isolation methods. Am J Physiol (1996) 1.22
Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol (1999) 1.21
Adrenergic modulation of ultrarapid delayed rectifier K+ current in human atrial myocytes. Circ Res (1996) 1.20
Characterization of an ultrarapid delayed rectifier potassium channel involved in canine atrial repolarization. J Physiol (1996) 1.17
Properties, expression and potential roles of cardiac K+ channel accessory subunits: MinK, MiRPs, KChIP, and KChAP. J Membr Biol (2003) 1.16
Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia. Circulation (1998) 1.15
Training of providers in embryo transfer: what is the minimum number of transfers required for proficiency? Hum Reprod (2001) 1.14
Effects of flecainide and quinidine on human atrial action potentials. Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues. Circulation (1990) 1.13
Ultrarapid delayed rectifier current inactivation in human atrial myocytes: properties and consequences. Am J Physiol (1998) 1.12
Tachycardia-induced changes in Na+ current in a chronic dog model of atrial fibrillation. Circ Res (1997) 1.12
Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine (2000) 1.11
Protein kinase C activates ATP-sensitive K+ current in human and rabbit ventricular myocytes. Circ Res (1996) 1.10
Atrial cell action potential parameter fitting using genetic algorithms. Med Biol Eng Comput (2005) 1.10
Nicotine is a potent blocker of the cardiac A-type K(+) channels. Effects on cloned Kv4.3 channels and native transient outward current. Circulation (2000) 1.10
Mechanisms of inactivation of L-type calcium channels in human atrial myocytes. Am J Physiol (1997) 1.10
Mechanism of flecainide's rate-dependent actions on action potential duration in canine atrial tissue. J Pharmacol Exp Ther (1993) 1.08
Alpha-adrenergic control of volume-regulated Cl- currents in rabbit atrial myocytes. Characterization of a novel ionic regulatory mechanism. Circ Res (1995) 1.08
Safety of dipyridamole testing in 73,806 patients: the Multicenter Dipyridamole Safety Study. J Nucl Cardiol (1998) 1.07
Ionic remodeling of cardiac Purkinje cells by congestive heart failure. Circulation (2001) 1.07
Slow delayed rectifier current and repolarization in canine cardiac Purkinje cells. Am J Physiol Heart Circ Physiol (2001) 1.07
Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness. Circulation (1993) 1.07
Of circles and spirals: bridging the gap between the leading circle and spiral wave concepts of cardiac reentry. Europace (2005) 1.06
Relative role of alkalosis and sodium ions in reversal of class I antiarrhythmic drug-induced sodium channel blockade by sodium bicarbonate. Circulation (1996) 1.06
Reductions in herpes simplex virus type 2 antibody titers after cognitive behavioral stress management and relationships with neuroendocrine function, relaxation skills, and social support in HIV-positive men. Psychosom Med (2001) 1.04
Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation. Circulation (2000) 1.03
Minimum Information about a Cardiac Electrophysiology Experiment (MICEE): standardised reporting for model reproducibility, interoperability, and data sharing. Prog Biophys Mol Biol (2011) 1.03
Expression of multiple subtypes of muscarinic receptors and cellular distribution in the human heart. Mol Pharmacol (2001) 1.03
Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes. Cardiovasc Res (2001) 1.00
Can cardiovascular clinical characteristics be identified and outcome models be developed from an in-patient claims database? Am J Cardiol (1999) 1.00
Effect of an evidence-based medicine seminar on participants' interpretations of clinical trials: a pilot study. Acad Med (2000) 1.00
Evidence that outwardly rectifying Cl- channels underlie volume-regulated Cl- currents in heart. Circ Res (1997) 1.00
Method for simultaneous epicardial and endocardial mapping of in vivo canine heart: application to atrial conduction properties and arrhythmia mechanisms. J Cardiovasc Electrophysiol (2001) 0.99
Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis (2001) 0.99
Potassium channel blocking properties of propafenone in rabbit atrial myocytes. J Pharmacol Exp Ther (1993) 0.99
Oxidative preconditioning and apoptosis in L-cells. Roles of protein kinase B and mitogen-activated protein kinases. J Biol Chem (2001) 0.98
Comparative mechanisms of 4-aminopyridine-resistant Ito in human and rabbit atrial myocytes. Am J Physiol (1995) 0.97
Alterations in regional myocardial distribution and arrhythmogenic effects of aprindine produced by coronary artery occlusion in the dog. Cardiovasc Res (1981) 0.97
Differences in rate dependence of transient outward current in rabbit and human atrium. Am J Physiol (1992) 0.97
Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation. Circ Res (1992) 0.96
Frequency-dependent effects of antiarrhythmic drugs on action potential duration and refractoriness of canine cardiac Purkinje fibers. J Pharmacol Exp Ther (1984) 0.95
Effects of class III antiarrhythmic drugs on transient outward and ultra-rapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther (1997) 0.94
Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. Circulation (1999) 0.94
A comparison of transient outward currents in canine cardiac Purkinje cells and ventricular myocytes. Am J Physiol Heart Circ Physiol (2000) 0.93
Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl J Med (1994) 0.92
Repolarization differences between guinea pig atrial endocardium and epicardium: evidence for a role of Ito. Am J Physiol (1991) 0.92
Mechanisms of ischemic preconditioning in rat hearts. Involvement of alpha 1B-adrenoceptors, pertussis toxin-sensitive G proteins, and protein kinase C. Circulation (1995) 0.91
Properties of sodium and potassium currents of cultured adult human atrial myocytes. Am J Physiol (1996) 0.90
Transmembrane chloride currents in human atrial myocytes. Am J Physiol (1996) 0.90
Effects of ambasilide, quinidine, flecainide and verapamil on ultra-rapid delayed rectifier potassium currents in canine atrial myocytes. Cardiovasc Res (2000) 0.90
Beta-blockers as antiarrhythmic agents. Handb Exp Pharmacol (2006) 0.90
The T-type Ca(2+) channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation (1999) 0.89
Adenosine-induced activation of ATP-sensitive K+ channels in excised membrane patches is mediated by PKC. Am J Physiol (1999) 0.89
Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs. Circulation (1995) 0.88
Experimental amitriptyline intoxication: electrophysiologic manifestations and management. J Cardiovasc Pharmacol (1984) 0.88
State-dependent barium block of wild-type and inactivation-deficient HERG channels in Xenopus oocytes. J Physiol (2000) 0.87
Artificial intelligence versus logistic regression statistical modelling to predict cardiac complications after noncardiac surgery. Clin Cardiol (1994) 0.87
Sustained outward current observed after I(to1) inactivation in rabbit atrial myocytes is a novel Cl- current. Am J Physiol (1992) 0.87
Adrenergic control of the ultrarapid delayed rectifier current in canine atrial myocytes. J Physiol (1999) 0.87
Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide. Circulation (1994) 0.87
Background and methods for the lovastatin restenosis trial after percutaneous transluminal coronary angioplasty. The Lovastatin Restenosis Trial Study Group. Am J Cardiol (1992) 0.86
Multivariate clinical models and quantitative dipyridamole-thallium imaging to predict cardiac morbidity and death after vascular reconstruction. J Vasc Surg (1991) 0.86
Multiple-dose vials: persistence of bacterial contaminants and infection control implications. Infect Control (1985) 0.86